The purpose of this protocol is to make Stanate (TM) \[stannsoporfin, tin-mesoporphyrin\] available to infants who meet the following criteria: 1. the infant has a very high level of bilirubin without an adequate clinical response to phototherapy; 2. the infant requires an exchange transfusion; and 3. the family refuses to allow the administration of blood products, particularly on religious grounds, such as within the Jehovah's Witness community.
Study Type
EXPANDED_ACCESS
Treatment with 4.5 mg/kg
William Beaumont Hospital
Royal Oak, Michigan, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.